ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Termination of a Material Definitive Agreement

ME Staff 8-k
-
0

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02.   Termination of a Material Definitive Agreement.

On November 22, 2016, Adaptimmune Therapeutics plc (the “Company”) received notices from Immunocore Limited (“Immunocore”) to end subleases of Building 91, Milton Park, Oxfordshire (“Building 91”) effective June 1, 2017.

The formal termination of these subleases is part of a plan, which the Company has worked on in collaboration with Immunocore, to ensure the smooth transition of the Company’s staff from Building 91 into the Company’s new 67,100 square foot building at Milton Park, Oxfordshire (“Building 60”) in the first half of 2017. Building 60 comprises laboratory and office space and has been designed to accommodate the Company’s research and development and U.K. corporate operations.

As previously reported, the Company entered into a lease of Building 60 directly with MEPC Milton Park, the owner of Milton Park, on October 24, 2016, following the completion of the building and to a lease agreement between the Company and MEPC Milton Park.


About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Recent Trading Information

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) closed its last trading session up +0.05 at 4.98 with 50,830 shares trading hands.